Duyuru • Feb 06
Embecta Corp. Announces Quarterly Cash Dividend, Payable on March 17, 2026 Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on March 17, 2026 to stockholders of record at the close of business on February 27, 2026. Duyuru • Dec 19
Embecta Corp., Annual General Meeting, Feb 11, 2026 Embecta Corp., Annual General Meeting, Feb 11, 2026. Duyuru • Nov 18
Embecta Corp. Announces Board Changes Embecta Corp. announced that on November 17, 2025, David A. Albritton, a member of the board of directors of the company, the Corporate Governance and Nominating Committee of the Board and the Technology, Quality and Regulatory Committee of the Board, notified the Company of his intention to resign due to personal reasons, effective immediately. Mr. Albritton has served as a director of the Company since April 2022. Mr. Albritton’s resignation was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. On November 17, 2025, LTG (Ret.) David F. Melcher, a member of the Board and the Non-Executive Chairman of the Board, notified the Company of his decision not to stand for re-election at the Company’s 2026 annual meeting of stockholders. LTG Melcher has served as a director of the Company since April 2022. LTG Melcher’s decision not to stand for reelection was not the result of any disagreement with the Company or any matter relating to its operations, policies or practices. In connection with the resignation of Mr. Albritton, the size of the Board was decreased from nine to eight members. The Company’s independent directors expect to appoint Devdatt (Dev) Kurdikar as the Chairman of the Board and Dr. Claire Pomeroy as the Board’s Lead Independent Director, each effective upon LTG Melcher’s departure from the Board at the Company’s 2026 annual meeting of stockholders. Dr. Pomeroy and Mr. Kurdikar have served on the Board since April 2022. Dr. Pomeroy currently serves as Chair of the Corporate Governance and Nominating Committee and as a member of the Technology, Quality and Regulatory Committee, and Mr. Kurdikar currently serves as the President and Chief Executive Officer of the Company. Duyuru • Nov 12
Embecta Corp. to Report Q4, 2025 Results on Nov 25, 2025 Embecta Corp. announced that they will report Q4, 2025 results on Nov 25, 2025 Duyuru • Aug 08
Embecta Corp. Declares Quarterly Cash Dividend, Payable on September 15, 2025 The Board of Directors of Embecta Corp. has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on September 15, 2025 to stockholders of record at the close of business on August 29, 2025. Duyuru • May 22
Embecta Corp. Re-Affirms Earnings Guidance for the Fiscal Year 2025 Embecta Corp. re-affirmed earnings guidance for the fiscal year 2025. For the year, the company expected Reported Revenues of $1,073 million - $1,090 million. Duyuru • Apr 22
Embecta Corp. to Report Q2, 2025 Results on May 09, 2025 Embecta Corp. announced that they will report Q2, 2025 results on May 09, 2025 Duyuru • Jan 24
Embecta Corp. to Report Q1, 2025 Results on Feb 06, 2025 Embecta Corp. announced that they will report Q1, 2025 results on Feb 06, 2025 Duyuru • Dec 20
Embecta Corp., Annual General Meeting, Feb 12, 2025 Embecta Corp., Annual General Meeting, Feb 12, 2025. Location: the hilton short hills, 41 john f. kennedy parkway, short hills, new jersey, United States Duyuru • Dec 03
Embecta Corp. Announces Executive Changes Embecta Corp. appointed Anthony Roth as Chief Accounting Officer and Corporate Controller of the Company and principal accounting officer of the Company, effective as of December 2, 2024. Prior to joining the Company, Mr. Roth, 51, served as Senior Vice President, Chief Accounting Officer for Ascential plc’s Digital Commerce business during 2023 and as Chief Accounting Officer and Corporate Controller for Summit Health, from 2020 to 2023. Prior to his time with Summit Health, he served as Senior Vice President, Finance and Corporate Controller with Phibro Animal Health Corporation. Mr. Roth, a certified public accountant, has also held various accounting and financial reporting positions across several companies, including Squarespace Inc., ConvaTec Inc. and Travelport Limited. In connection with the appointment of Mr. Roth, Jake Elguicze stepped down as the Company’s principal accounting officer, effective December 2, 2024. Mr. Elguicze will continue to serve as the Company’s Chief Financial Officer and principal financial officer. Duyuru • Dec 01
Embecta Corp. announced delayed annual 10-K filing On 11/29/2024, Embecta Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Duyuru • Nov 13
Embecta Corp. to Report Q4, 2024 Results on Nov 26, 2024 Embecta Corp. announced that they will report Q4, 2024 results on Nov 26, 2024 Duyuru • Sep 03
Embecta Corp. Receives 510(k) Clearance from the U.S. Food and Drug Administration for Disposable Insulin Delivery System Embecta Corp. announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary disposable insulin delivery system. Indicated for adults who require insulin to manage diabetes, including both type 1 (T1D) and type 2 (T2D), the system includes a tubeless patch pump design with a 300-unit insulin reservoir that was informed by feedback from people with T2D and their healthcare providers. The system includes a wearable, fully disposable patch pump that provides adjustable basal and bolus insulin for up to three days, depending on the needs of the user. The patch pump features a 300-unit insulin reservoir that accommodates people who have higher daily insulin needs, which is typically true of people with T2D. For such people, the on-market patch pumps may not hold enough insulin to meet their needs for three days. For example, a recent embecta-sponsored study showed that a 300-unit insulin reservoir would meet the needs of 64% of adults with T2D for three-day wear, while a 200-unit reservoir would only meet the needs of 38% of that same population. In addition to the patch pump, the system comprises a locked-down controller featuring Bluetooth wireless technology with a color touchscreen designed to create a simplified interface and user experience. embecta’s patch pump development program also includes plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission. Duyuru • Jul 19
Embecta Corp. to Report Q3, 2024 Results on Aug 09, 2024 Embecta Corp. announced that they will report Q3, 2024 results on Aug 09, 2024 Duyuru • Apr 24
Embecta Corp. to Report Q2, 2024 Results on May 09, 2024 Embecta Corp. announced that they will report Q2, 2024 results on May 09, 2024 Duyuru • Jan 25
Embecta Corp. to Report Q1, 2024 Results on Feb 09, 2024 Embecta Corp. announced that they will report Q1, 2024 results on Feb 09, 2024 Duyuru • Jan 09
Embecta Corp. Announces Food and Drug Administration 510(K) Submission for Insulin Patch Pump Embecta Corp. announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system. embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission. Duyuru • Dec 20
Embecta Corp., Annual General Meeting, Feb 07, 2024 Embecta Corp., Annual General Meeting, Feb 07, 2024, at 08:00 US Eastern Standard Time. Location: Hilton Short Hills, 41 John F. Kennedy Parkway Short Hills New Jersey United States Agenda: To consider the election as directors of the three nominees named in the attached proxy statement for a two-year term; to consider the ratification of the selection of the independent registered public accounting firm; to consider an advisory vote to approve named executive officer compensation; and to discuss the approval of an amendment to the Embecta 2022 Employee and Director Equity-Based Compensation Plan. Duyuru • Jul 06
Embecta Corp. Announces Resignation of Ajay Kumar as Chief Human Resources Officer, Effective July 16, 2023 On June 29, 2023, Ajay Kumar, the Chief Human Resources Officer (CHRO) of Embecta Corp. and the Company mutually agreed to Mr. Kumar’s resignation from his role as CHRO, effective July 16, 2023. Reported Earnings • May 17
Second quarter 2023 earnings released: EPS: US$0.24 (vs US$1.38 in 2Q 2022) Second quarter 2023 results: EPS: US$0.24 (down from US$1.38 in 2Q 2022). Revenue: US$277.1m (flat on 2Q 2022). Net income: US$14.0m (down 82% from 2Q 2022). Profit margin: 5.1% (down from 29% in 2Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 9.1% growth forecast for the Global Medical Equipment industry. Board Change • May 17
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Feb 15
First quarter 2023 earnings released First quarter 2023 results: EPS: US$0.62. Revenue: US$275.7m (down 4.7% from 1Q 2022). Net income: US$35.2m (down 64% from 1Q 2022). Profit margin: 13% (down from 34% in 1Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 8.7% growth forecast for the Global Medical Equipment industry. Board Change • Jan 30
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Jan 25
Embecta Corp. to Report Q1, 2023 Results on Feb 14, 2023 Embecta Corp. announced that they will report Q1, 2023 results on Feb 14, 2023 Board Change • Jan 05
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Dec 05
Investor sentiment improved over the past week After last week's 22% share price gain to Mex$666, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 25x in the Medical Equipment industry globally. Board Change • Nov 16
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Oct 28
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. No experienced directors. No highly experienced directors. Independent Director Bob Hombach is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Duyuru • Oct 01
Embecta Corp., Annual General Meeting, Feb 09, 2023 Embecta Corp., Annual General Meeting, Feb 09, 2023. Reported Earnings • Aug 16
Third quarter 2022 earnings released Third quarter 2022 results: Net income: US$62.4m (up US$62.4m from 3Q 2021). Over the next year, revenue is expected to shrink by 2.5% compared to a 19% growth forecast for the Medical Equipment industry in Mexico. Duyuru • Jul 06
Embecta Corp. to Report Q3, 2022 Results on Aug 15, 2022 Embecta Corp. announced that they will report Q3, 2022 results Pre-Market on Aug 15, 2022 Duyuru • May 14
Embecta Corp. Provides Revenue Guidance for the Last Six Months of Fiscal Year 2022 Embecta Corp. provided revenue guidance for the last six months of fiscal year 2022. For the period, the company expects total revenue of approximately $555 million, representing a decrease of approximately 7.0%, as compared to total revenue of $596 million for the last six months of fiscal year 2021. Duyuru • Apr 20
Embecta Corp. to Report Q2, 2022 Results on May 13, 2022 Embecta Corp. announced that they will report Q2, 2022 results Pre-Market on May 13, 2022